Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) rose more than 3% at the end of the session ATTC authorized GSK agency to say the company's path to overseas is clear

The Zhitong Finance App learned that Hewang Pharmaceutical (00013) rose more than 3% at the end of the session. As of press release, it rose 2.2% to HK$21.9, with a turnover of HK$905.696 million.

According to the news, on September 3, the company announced that it had reached an exclusive license agreement with GSK for HMPL-A830 (KRAS-EGFR ATTC), and GSK received overseas equity with a down payment/milestone of US$1.118 billion. Huafu Securities said it is optimistic that HMPL-A830 is expected to use a differentiation mechanism to enter the CRC's KRAS mutation and is not satisfied with the market. It is recommended to focus on tracking the Phase I data reading.

Huatai Securities said that A830 received a major BD, verifying the global value of the ATTC platform. The company's 2H26 is expected to launch Global Phase I, while A251 and A580 Global Phase I are progressing smoothly. Various molecules are expected to enter clinical trials one after another, and they are optimistic that they will continue to go overseas. Previously, the company and MNC such as AstraZeneca and Takeda had reached multiple overseas BDs, and overseas commercialization of related molecules is gradually being implemented. Among them, overseas sales of furoquintinib continued to grow steadily, and obtained the global PFS/III phase of 8M26 sevotinib 2LNSCLC OS is positive, and the FDA is expected to report production.